The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Phase I study of IOA-244 in follicular lymphoma
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, comments on the preliminary findings of a Phase I study evaluating IOA-244, a PI3Kδ inhibitor, in patients with follicular lymphoma (FL) (NCT04328844). Prof. Carlo-Stella explains that this combination appears to be well-tolerated. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
